Committee for Orphan Medicinal Products (COMP)
Draft agenda for the meeting on 16-18 April 2024

Chair: Violeta Stoyanova-Beninska – Vice-Chair: Armando Magrelli

16 April 2024, 09:00-19:30, room 2A
17 April 2024, 08:30-19:30, room 2A
18 April 2024, 08:30-17:00, room 2A

Health and safety information
In accordance with the Agency’s health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers
Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the COMP meeting reports once the procedures are finalised.

Of note, this agenda is a working document primarily designed for COMP members and the work the Committee undertakes.

Note on access to documents
Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to ongoing procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).
Table of contents

1. Introduction 5
   1.1. Welcome and declarations of interest of members and experts 5
   1.2. Adoption of agenda 5
   1.3. Adoption of the minutes 5

2. Applications for orphan medicinal product designation 5
   2.1. For opinion 5
      2.1.1. - EMA/OD/0000133472 5
      2.1.2. - EMA/OD/0000161033 5
      2.1.3. - EMA/OD/0000156967 5
      2.1.4. - EMA/OD/0000158039 5
   2.2. For discussion / preparation for an opinion 5
      2.2.1. - EMA/OD/0000133251 5
      2.2.2. - EMA/OD/0000155489 6
      2.2.3. - EMA/OD/0000159474 6
      2.2.4. - EMA/OD/0000159798 6
      2.2.5. - EMA/OD/0000161987 6
      2.2.6. - EMA/OD/0000162667 6
      2.2.7. - EMA/OD/0000162753 6
      2.2.8. - EMA/OD/0000164186 6
      2.2.9. - EMA/OD/0000164451 6
      2.2.10. - EMA/OD/0000165028 6
      2.2.11. - EMA/OD/0000165289 7
      2.2.12. - EMA/OD/0000165562 7
      2.2.13. - EMA/OD/0000165806 7
      2.2.14. - EMA/OD/0000165835 7
      2.2.15. - EMA/OD/0000165872 7
      2.2.16. - EMA/OD/0000166376 7
   2.3. Revision of the COMP opinions 7
   2.4. Amendment of existing orphan designations 7
   2.5. Appeal 7
   2.6. Nominations 8
      2.6.1. New applications for orphan medicinal product designation - Appointment of COMP rapporteurs 8
   2.7. Evaluation on-going 8

3. Requests for protocol assistance with significant benefit question 8
   3.1. Ongoing procedures 8
      3.1.1. - 8
3.1.2. - .............................................................................................................................. 8

4. Review of orphan designation for orphan medicinal products at time of initial marketing authorisation 8

4.1. Orphan designated products for which CHMP opinions have been adopted .......... 8
4.1.1. Agilus – dantrolene sodium, hemiheptahydrate - EMEA/H/C/006009, EU/3/21/2443, EMA/OD/0000102465 ........................................................................................................... 8

4.2. Orphan designated products for discussion prior to adoption of CHMP opinion ...... 9
4.2.1. efanesoctocog alfa - EMEA/H/C/005968, EU/3/19/2176, EMA/OD/0000160184 ............ 9

4.3. Appeal .................................................................................................................... 9

4.4. On-going procedures ............................................................................................ 9

4.5. Orphan Maintenance Reports .............................................................................. 9

5. Review of orphan designation for authorised orphan medicinal products at time marketing authorisation extension 9

5.1. After adoption of CHMP opinion ........................................................................ 9

5.2. Prior to adoption of CHMP opinion ..................................................................... 9

5.3. Appeal .................................................................................................................... 9
5.3.1. Aspaveli – pegcetacoplan - EMEA/H/C/005553/II/0011, EU/3/17/1873, EMA/OD/0000172113 ......................................................................................................................................... 9

5.4. On-going procedures ............................................................................................ 10

6. Application of Article 8(2) of the Orphan Regulation 10

7. Organisational, regulatory and methodological matters 10

7.1. Mandate and organisation of the COMP .............................................................. 10

7.1.1. COMP membership .......................................................................................... 10

7.1.2. Vote by proxy .................................................................................................. 10

7.1.3. Strategic Review & Learning meetings ............................................................. 10

7.1.4. Protocol Assistance Working Group (PAWG) .................................................. 10

7.1.5. COMP Decisions Database .......................................................................... 10

7.1.6. Mandate of COMP Chairperson and Vice-Chairperson – call for nominations ... 10

7.2. Coordination with EMA Scientific Committees or CMDh-v .............................. 10

7.2.1. Recommendation on eligibility to PRIME – report ........................................ 10

7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups ...... 11

7.3.1. Working Party with Patients’ and Consumers’ Organisations (PCWP) and Working Party with Healthcare Professionals’ Organisations (HCPWP) ............................................................. 11

7.3.2. Innovation Task Force (ITF) meetings ............................................................. 11

7.3.3. Oncology Working Party (ONCWP) ................................................................. 11

7.3.4. Committee representatives at Scientific Advice Working Party (SAWP) - call for interest... 11

7.4. Cooperation within the EU regulatory network ................................................. 11
7.4.1. European Commission

7.5. Cooperation with International Regulators

7.5.1. Food and Drug Administration (FDA)

7.5.2. Japanese Pharmaceuticals and Medical Devices Agency (PMDA)

7.5.3. Therapeutic Goods Administration (TGA), Australia

7.5.4. Health Canada

7.6. Contacts of the COMP with external parties and interaction with the Interested Parties to the Committee

7.7. COMP work plan

7.8. Planning and reporting

7.8.1. List of all applications submitted/expected and the COMP rapporteurship distribution of valid applications submitted in 2024

7.8.2. Overview of orphan marketing authorisations/applications

8. Any other business

8.1. Collaborare project: kick off project and presentation of the tool

9. Explanatory notes
1. Introduction

1.1. Welcome and declarations of interest of members and experts

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the COMP plenary session to be held 16-18 April 2024. See April 2024 COMP minutes (to be published post May 2024 COMP meeting).

1.2. Adoption of agenda

COMP agenda for 16-18 April 2024.

1.3. Adoption of the minutes

COMP minutes for 12-14 March 2024.

2. Applications for orphan medicinal product designation

2.1. For opinion

2.1.1. - EMA/OD/0000133472

Treatment of tuberculosis

**Action:** For adoption, Oral explanation to be held on 16 April 2024 at 14:00

2.1.2. - EMA/OD/0000161033

Treatment of hypophosphatasia

**Action:** For adoption, Oral explanation to be held on 16 April 2024 at 16:00

2.1.3. - EMA/OD/0000156967

Treatment of familial chylomicronemia syndrome (FCS)

**Action:** For adoption, Oral explanation to be held on 17 April 2024 at 15:30

2.1.4. - EMA/OD/0000158039

Treatment of heparin-induced thrombocytopenia

**Action:** For adoption, Oral explanation to be held on 17 April 2024 at 14:00

2.2. For discussion / preparation for an opinion

2.2.1. - EMA/OD/0000133251

Treatment of idiopathic hypersomnia

**Action:** For discussion/ adoption
2.2.2.  - EMA/OD/0000155489

Treatment of cutaneous T-cell lymphoma

**Action:** For discussion/adoption

2.2.3.  - EMA/OD/0000159474

Treatment of Duchenne muscular dystrophy

**Action:** For discussion/adoption

2.2.4.  - EMA/OD/0000159798

Treatment of recombination-activating gene 1 (RAG1) deficiency

**Action:** For discussion/adoption

2.2.5.  - EMA/OD/0000161987

Treatment of epidermolysis bullosa

**Action:** For discussion/adoption

2.2.6.  - EMA/OD/0000162667

Treatment of hepatocellular carcinoma

**Action:** For discussion/adoption

2.2.7.  - EMA/OD/0000162753

Treatment of acute lymphoblastic leukaemia

**Action:** For discussion/adoption

2.2.8.  - EMA/OD/0000164186

Treatment of phenylalanine hydroxylase deficiency

**Action:** For discussion/adoption

2.2.9.  - EMA/OD/0000164451

Treatment of MECP2 duplication syndrome

**Action:** For discussion/adoption

2.2.10. - EMA/OD/0000165028

Treatment of small cell lung cancer

**Action:** For discussion/adoption
2.2.11. - EMA/OD/0000165289

Treatment of DiGeorge's syndrome

**Action:** For discussion/adoption

2.2.12. - EMA/OD/0000165562

Treatment of neonatal seizures

**Action:** For discussion/adoption

2.2.13. - EMA/OD/0000165806

Treatment of acute radiation syndrome (ARS)

**Action:** For discussion/adoption

2.2.14. - EMA/OD/0000165835

Treatment of signet ring cell carcinoma

**Action:** For discussion/adoption

2.2.15. - EMA/OD/0000165872

Treatment of xeroderma pigmentosum (XP)

**Action:** For discussion/adoption

2.2.16. - EMA/OD/0000166376

Treatment of arrhythmogenic cardiomyopathy caused by pathogenic mutations in the *PKP2* gene

**Action:** For discussion/adoption

2.3. **Revision of the COMP opinions**

None

2.4. **Amendment of existing orphan designations**

None

2.5. **Appeal**

None
2.6. **Nominations**

2.6.1. New applications for orphan medicinal product designation - Appointment of COMP rapporteurs

*Action*: For adoption

OMPDP applications - appointment of rapporteurs at the 16-18 April 2024 COMP meeting

2.7. **Evaluation on-going**

24 applications for orphan designation will not be discussed as evaluation is ongoing.

*Action*: For information

3. **Requests for protocol assistance with significant benefit question**

3.1. **Ongoing procedures**

3.1.1. Treatment of neurofibromatosis type 1

*Action*: For adoption

3.1.2. Treatment of pyruvate kinase deficiency

*Action*: For adoption

4. **Review of orphan designation for orphan medicinal products at time of initial marketing authorisation**

4.1. **Orphan designated products for which CHMP opinions have been adopted**

4.1.1. Agilus – dantrolene sodium, hemiheptahydrate - EMEA/H/C/006009, EU/3/21/2443, EMA/OD/0000102465

Norgine B.V.; Treatment of malignant hyperthermia

*Action*: For adoption, Oral explanation to be held on 17 April 2024 at 11:00
4.2. Orphan designated products for discussion prior to adoption of CHMP opinion

4.2.1. efanesoctocog alfa - EMEA/H/C/005968, EU/3/19/2176, EMA/OD/0000160184  
Swedish Orphan Biovitrum AB (publ); Treatment of haemophilia A  
**Action:** For adoption

4.3. Appeal

None

4.4. On-going procedures  
**Action:** For information

Review of orphan designation for OMP for MA - On-going procedures

4.5. Orphan Maintenance Reports  
**Action:** For information

5. Review of orphan designation for authorised orphan medicinal products at time marketing authorisation extension

5.1. After adoption of CHMP opinion

None

5.2. Prior to adoption of CHMP opinion

Amgen Europe B.V.; Treatment of acute lymphoblastic leukaemia  
**Action:** For discussion/adoption

5.3. Appeal

5.3.1. Aspaveli – pegcetacoplan - EMEA/H/C/005553/II/0011, EU/3/17/1873, EMA/OD/0000172113  
Swedish Orphan Biovitrum AB (publ); Treatment of paroxysmal nocturnal haemoglobinuria  
CHMP Rapporteur: Alexandre Moreau; CHMP Co-Rapporteur: Selma Arapovic  
**Action:** For adoption, Oral explanation to be held on 16 April 2024 at 11:00
5.4. **On-going procedures**

**Action:** For information

Review of orphan designation for OMP for MA extension - On-going procedures

6. **Application of Article 8(2) of the Orphan Regulation**

None

7. **Organisational, regulatory and methodological matters**

7.1. **Mandate and organisation of the COMP**

7.1.1. COMP membership

**Action:** For information

7.1.2. Vote by proxy

**Action:** For information

7.1.3. **Strategic Review & Learning meetings**

Preliminary feedback from the SRLM meeting in Leuven under the Belgian Presidency of the Council of the EU

**Action:** For discussion

7.1.4. **Protocol Assistance Working Group (PAWG)**

Proposed meeting time on 16 April 2024 at 13:00

PAWG draft agenda for 16 April 2024 meeting

7.1.5. **COMP Decisions Database**

**Action:** For discussion

7.1.6. **Mandate of COMP Chairperson and Vice-Chairperson – call for nominations**

**Action:** For information

7.2. **Coordination with EMA Scientific Committees or CMDh-v**

7.2.1. **Recommendation on eligibility to PRIME – report**

PRIME eligibility requests - list of adopted outcomes March 2024
7.3. **Coordination with EMA Working Parties/Working Groups/Drafting Groups**

7.3.1. **Working Party with Patients’ and Consumers’ Organisations (PCWP) and Working Party with Healthcare Professionals’ Organisations (HCPWP)**

None

7.3.2. **Innovation Task Force (ITF) meetings**

*Action*: For discussion

Upcoming ITF meetings

7.3.3. **Oncology Working Party (ONCWP)**

Outcome of the ONCWP consultation

*Action*: For discussion

7.3.4. **Committee representatives at Scientific Advice Working Party (SAWP) - call for interest**

*Action*: For discussion

Following departure of a joint COMP-SAWP alternate, a call for expression of interests will be launched.

7.4. **Cooperation within the EU regulatory network**

7.4.1. **European Commission**

None

7.5. **Cooperation with International Regulators**

7.5.1. **Food and Drug Administration (FDA)**

None

7.5.2. **Japanese Pharmaceuticals and Medical Devices Agency (PMDA)**

None

7.5.3. **Therapeutic Goods Administration (TGA), Australia**

None

7.5.4. **Health Canada**

None
7.6. Contacts of the COMP with external parties and interaction with the Interested Parties to the Committee

None

7.7. COMP work plan

None

7.8. Planning and reporting

7.8.1. List of all applications submitted/expected and the COMP rapporteurship distribution of valid applications submitted in 2024

**Action:** For information

7.8.2. Overview of orphan marketing authorisations/applications

**Action:** For information

8. Any other business

8.1. Collaborare project: kick off project and presentation of the tool

**Action:** For discussion

9. Explanatory notes

The notes below give a brief explanation of the main sections and headings in the COMP agenda and should be read in conjunction with the agenda or the minutes.

**Abbreviations / Acronyms**

CHMP: Committee for Medicinal Product for Human Use
COMP: Committee for Orphan Medicinal Products
EC: European Commission
OD: Orphan Designation
PA: Protocol Assistance
PDCO: Paediatric Committee
PRAC: Pharmacovigilance and Risk Assessment Committee
SA: Scientific Advice
SAWP: Scientific Advice Working Party

**Orphan Designation** *(section 2 Applications for orphan medicinal product designation)*

The orphan designation is the appellation given to certain medicinal products under development that are intended to diagnose, prevent or treat rare conditions when they...
meet a pre-defined set of criteria foreseen in the legislation. Medicinal products which get the orphan status benefit from several incentives (fee reductions for regulatory procedures (including protocol assistance), national incentives for research and development, 10-year market exclusivity) aiming at stimulating the development and availability of treatments for patients suffering from rare diseases.

Orphan Designations are granted by Decisions of the European Commission based on opinions from the COMP. Orphan designated medicinal products are entered in the Community Register of Orphan Medicinal Products.

**Protocol Assistance** *(section 3 Requests for protocol assistance with significant benefit question)*

The protocol assistance is the help provided by the Agency to the sponsor of an orphan medicinal product, on the conduct of the various tests and trials necessary to demonstrate the quality, safety and efficacy of the medicinal product in view of the submission of an application for marketing authorisation.

**Sponsor**

Any legal or physical person, established in the Community, seeking to obtain or having obtained the designation of a medicinal product as an orphan medicinal product.

**Maintenance of Orphan Designation** *(section 4 Review of orphan designation for orphan medicinal products for marketing authorisation).*

At the time of marketing authorisation, the COMP will check if all criteria for orphan designation are still met. The designated orphan medicinal product should be removed from the Community Register of Orphan Medicinal Products if it is established that the criteria laid down in the legislation are no longer met.

For a list of acronyms and abbreviations, see:

*Abbreviations used in EMA scientific committees & CMD documents and in relation to EMA’s regulatory activities*

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/